Banner Health

Banner Health, doing business as Banner Research Institute, is a non-profit healthcare system headquartered in Phoenix, Arizona, that operates as both a federal prime recipient (45% of recent awards) and sub-recipient (55%) on research grants and clinical service contracts, with no federal procurement set-asides across its award footprint. The organization serves 21 distinct federal agencies through a network of hospital, medical imaging, laboratory, and research subsidiary entities. Banner's federal footprint spans clinical trial operations, biospecimen supply, advanced diagnostic testing, and medical education funding, with core strength in neurodegenerative disease research infrastructure and brain tissue banking.

Banner's customer base is heavily concentrated in two federal agencies that account for 90% of combined potential value. The National Institute on Aging is the dominant customer by award volume, with 60 awards carrying $7.3 million combined potential value, reflecting Banner's established role as a supplier of frozen human brain tissue from its Brain and Body Donation Program, provider of NULISA proteomic liquid biopsy testing for Alzheimer's disease biomarker identification, and sub-recipient on multiple NIA-funded research grants. The Department of Veterans Affairs Veterans Integrated Service Network 22 anchors the value concentration with 10 awards carrying $59 million combined potential value, predominantly driven by a single indefinite delivery contract (VA25816D0008) worth $41.9 million that funds graduate medical education base year support through June 2030. The National Cancer Institute (9 awards), National Institute of Neurological Disorders and Stroke (4 awards), and Health Resources and Services Administration (3 awards) represent secondary customer relationships. The tension between the two rankings reflects Banner's dual positioning: NIA generates sustained volume through modest research supply and grant sub-award work, while VA's single large IDC contract represents episodic but mission-critical clinical education funding that skews dollars sharply away from the research sector.

Banner's prime contract work is concentrated in medical and laboratory services. Recent prime purchases include a $6.9 million sole-source purchase order from the National Institute on Aging (through July 31, 2029) for NULISA proteomic liquid biopsy testing services to identify biomarkers associated with Alzheimer's disease and related dementias, leveraging Banner's validated and biobanked quality control cohort that the source notes cannot be replicated without unacceptable delay or scientific risk; a $45,220 purchase order from the National Institute of Diabetes and Digestive and Kidney Diseases for functional magnetic resonance imaging scan processing pipeline development, data transfer, and analysis services performed in Bethesda, Maryland (through August 30, 2027); and multiple five-figure purchase orders from the National Institute on Aging for supply of research materials including postmortem human brain specimens, cerebellar cortex tissue samples, and lab and glassware supplies supporting ongoing research infrastructure.

Banner operates as a sub-recipient on at least 65 federal research grants, primarily under National Institute on Aging and National Cancer Institute programs. Recurring sub-award work includes provision of frozen human brain tissue samples and neuropathological expertise from Banner's Brain and Body Donation Program (chartered since 1997 under Dr. Thomas Beach) to prime recipients including the University of California Irvine, University of California San Diego, UCLA, Boston University, University of Washington, and J. David Gladstone Institutes for research on Alzheimer's disease pathology, vascular dementia, neurodegeneration, and post-mortem tissue characterization. Banner also serves as a sub-recipient site on major multicenter clinical trials under prime grantees including Arizona State University, University of New Mexico (as part of an NIH-sponsored Arizona Alzheimer's Disease Research Center), Stanford University, and Boston University (DIAGNOSE CTE and pneumonia pathophysiology studies), where Banner contributes clinical infrastructure, imaging analysis expertise, rapid autopsy capability, and research participant enrollment. Banner Health is a named prime recipient on two active National Institute on Aging project grants: an Alzheimer's Prevention Initiative ADAD Colombia Trial grant awarded September 1, 2024 (through August 31, 2029), and a Tracer Harmonization for Amyloid and Tau PET Imaging grant awarded August 1, 2022 (through July 31, 2027).

Activity has grown modestly over the past five years, with 10 awards in 2022, 12 in 2023, 23 in 2024, 13 in 2025, and 14 in 2026. The recompete cliff in the next twenty-four months is minimal; only four awards (combined potential value $45 thousand) face ultimate completion inside that window. The modest recompete exposure masks the underlying concentration risk: the single $41.9 million VA graduate medical education IDC represents the lion's share of Banner's federal contract dollars and therefore anchors recompete vulnerability outside the twenty-four-month window once that vehicle approaches expiration. By NAICS, Banner's award distribution spans General Medical and Surgical Hospitals (11 awards), Colleges, Universities, and Professional Schools (9 awards, reflecting Banner's research partnerships), Biological Product Manufacturing and Testing Laboratories (3 awards each), and Blood and Organ Banks (3 awards). PSC distribution reflects the clinical and laboratory nature of the work: Medical-Surgery (7 awards), Reference Laboratory Testing (5 awards), Drugs and Biologicals (4 awards), and Laboratory Equipment and Supplies (4 awards).

Banner Health operates as the parent of 52 named subsidiaries, including Banner-University Medical Center Tucson Campus, Banner Imaging Services, Banner Poison Control Center, and others, many of which carry specialized clinical or operational capability framing. The Arizona Alzheimer's Consortium, Arizona Alzheimer's Disease Research Center, and Banner Alzheimer's Institute—operational units within the structure—surface Banner's deep investment in neurodegenerative disease research infrastructure and represent the operational spine of its federal research footprint.